DermTech is the global leader in molecular dermatology. Our patented technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. Using this technology, we market and develop non-invasive gene expression tests to aid the clinical diagnosis of skin cancer, to assess inflammatory diseases, and to personalize drug treatment. Our mission is to transform dermatology by delivering highly accurate, objective information to physicians that improves care, reduces costs, and improves patient satisfaction.
Kevin Sun, Chief Financial Officer
- DermTech Presents at Canaccord Genuity MedTech & Diagnostics Forum | November 21, 2019